Filing Flows › Northwest Biotherapeutics (NWBO) › Who owns the stock
Who owns Northwest Biotherapeutics (NWBO) stock
8 funds reported Northwest Biotherapeutics (NWBO) shares in their latest 13F filings, worth $529K in all. The largest holder is Compass Financial Management LLC ($227K). Last quarter 1 fund added to their stakes and 0 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Compass Financial Management LLC | 1,215,500 | $227K | base | 2026-06-30 |
| Kelleher Financial Advisors | 800,000 | $149K | increase | 2026-06-30 |
| Moloney Securities Asset Management, LLC | 534,710 | $128K | increase | 2025-09-30 |
| VSM Wealth Advisory, LLC | 80,574 | $15K | unchanged | 2026-06-30 |
| Williams Jones Wealth Management, LLC. | 25,000 | $5K | unchanged | 2026-06-30 |
| AlphaMark Advisors, LLC | 14,007 | $4K | base | 2024-12-31 |
| McIlrath & Eck, LLC | 600 | $124 | new | 2026-03-31 |
| Hantz Financial Services | 250 | $0 | unchanged | 2026-06-30 |
Northwest Biotherapeutics' latest quarter
Northwest Biotherapeutics, Q2 2026: revenue $807K (+516% year over year), net loss $15.4M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most NWBO stock?
By the latest 13F filings: Compass Financial Management LLC ($227K); Kelleher Financial Advisors ($149K); Moloney Securities Asset Management, LLC ($128K); VSM Wealth Advisory, LLC ($15K); Williams Jones Wealth Management, LLC. ($5K).
What is the short interest in NWBO?
73,131,113 shares were sold short at the 2026-10-15 settlement, -4.77% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.